» Articles » PMID: 34302613

Clinical Factors Associated with Composition of Lung Microbiota and Important Taxa Predicting Clinical Prognosis in Patients with Severe Community-acquired Pneumonia

Overview
Journal Front Med
Specialty General Medicine
Date 2021 Jul 24
PMID 34302613
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Few studies have described the key features and prognostic roles of lung microbiota in patients with severe community-acquired pneumonia (SCAP). We prospectively enrolled consecutive SCAP patients admitted to ICU. Bronchoscopy was performed at bedside within 48 h of ICU admission, and 16S rRNA gene sequencing was applied to the collected bronchoalveolar lavage fluid. The primary outcome was clinical improvements defined as a decrease of 2 categories and above on a 7-category ordinal scale within 14 days following bronchoscopy. Sixty-seven patients were included. Multivariable permutational multivariate analysis of variance found that positive bacteria lab test results had the strongest independent association with lung microbiota (R = 0.033; P = 0.018), followed by acute kidney injury (AKI; R = 0.032; P = 0.011) and plasma MIP-1β level (R = 0.027; P = 0.044). Random forest identified that the families Prevotellaceae, Moraxellaceae, and Staphylococcaceae were the biomarkers related to the positive bacteria lab test results. Multivariable Cox regression showed that the increase in α-diversity and the abundance of the families Prevotellaceae and Actinomycetaceae were associated with clinical improvements. The positive bacteria lab test results, AKI, and plasma MIP-1β level were associated with patients' lung microbiota composition on ICU admission. The families Prevotellaceae and Actinomycetaceae on admission predicted clinical improvements.

Citing Articles

Factors based on Cox regression modeling to analyze the prognostic impact of fiberoptic bronchoscopic bronchoalveolar lavage on children with severe pneumonia.

Ma W, Wang Y, Dang Q, Zhang X Am J Transl Res. 2025; 16(12):7645-7655.

PMID: 39822555 PMC: 11733319. DOI: 10.62347/OGZD3131.


Mapping Host-Microbe Omics Interactions in Severe Community-acquired Pneumonia.

Ji H, Liu G Am J Respir Cell Mol Biol. 2024; .

PMID: 39137326 PMC: 11707665. DOI: 10.1165/rcmb.2024-0346ED.


Predictors of mortality in severe pneumonia patients: a systematic review and meta-analysis.

Xie K, Guan S, Kong X, Ji W, Du C, Jia M Syst Rev. 2024; 13(1):210.

PMID: 39103964 PMC: 11302088. DOI: 10.1186/s13643-024-02621-1.


Alterations of lung microbiota in lung transplant recipients with pneumocystis jirovecii pneumonia.

Lian Q, Song X, Yang J, Wang L, Xu P, Wang X Respir Res. 2024; 25(1):125.

PMID: 38486264 PMC: 10941442. DOI: 10.1186/s12931-024-02755-9.


Lung microbiome on admission in critically ill patients with acute bacterial and viral pneumonia.

Marimon J, Sorarrain A, Ercibengoa M, Azcue N, Alonso M, Vidaur L Sci Rep. 2023; 13(1):17724.

PMID: 37853062 PMC: 10584954. DOI: 10.1038/s41598-023-45007-4.


References
1.
Liapikou A, Rosales-Mayor E, Torres A . The management of severe community acquired pneumonia in the intensive care unit. Expert Rev Respir Med. 2014; 8(3):293-303. DOI: 10.1586/17476348.2014.896202. View

2.
Espinoza R, Lapa E Silva J, Bergmann A, de Oliveira Melo U, Calil F, Santos R . Factors associated with mortality in severe community-acquired pneumonia: A multicenter cohort study. J Crit Care. 2018; 50:82-86. DOI: 10.1016/j.jcrc.2018.11.024. View

3.
Phua J, Dean N, Guo Q, Kuan W, Lim H, Lim T . Severe community-acquired pneumonia: timely management measures in the first 24 hours. Crit Care. 2016; 20:237. PMC: 5002335. DOI: 10.1186/s13054-016-1414-2. View

4.
Li H, Guo Q, Song W, Zhou Y, Li M, Chen X . Mortality among severe community-acquired pneumonia patients depends on combinations of 2007 IDSA/ATS minor criteria. Int J Infect Dis. 2015; 38:141-5. DOI: 10.1016/j.ijid.2015.07.026. View

5.
Torres A, Chalmers J, Dela Cruz C, Dominedo C, Kollef M, Martin-Loeches I . Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med. 2019; 45(2):159-171. PMC: 7094947. DOI: 10.1007/s00134-019-05519-y. View